Trial Profile
A Phase III, Randomized,Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of SHR-1210 in Combination With Carboplatin and Paclitaxel Versus Placebo in Combination With Carboplatin and Paclitaxel in First-Line Stage IV Squamous Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CameL-sq
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Dec 2021 Primary endpoint of progression-free survival has been met, according to results published in the Journal of Thoracic Oncology.
- 16 Dec 2021 Results published in the Journal of Thoracic Oncology
- 12 Mar 2021 Planned End Date changed from 28 Feb 2021 to 31 Dec 2021.